Sign up to save your podcasts
Or
Share Addressing Patient Management in ASCVD Risk Reduction: A Collaborative Approach
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Addressing Patient Management in ASCVD Risk Reduction: A Collaborative Approach
CME credits: 1.00
Valid until: 30-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/addressing-patient-management-in-ascvd-risk-reduction-a-collaborative-approach-broadcast-replay/15310/
We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A collaborative approach to addressing residual cardiovascular risk across a variety of risk factors that goes beyond LDL-C-lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients will benefit from a review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 1.00
Valid until: 30-08-2024
Claim your CME credit at https://reachmd.com/programs/cme/addressing-patient-management-in-ascvd-risk-reduction-a-collaborative-approach-broadcast-replay/15310/
We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A collaborative approach to addressing residual cardiovascular risk across a variety of risk factors that goes beyond LDL-C-lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients will benefit from a review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.
=